Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Stock Information for Reviva Pharmaceuticals Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Reviva Pharmaceuticals Holdings Inc.

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
Cardiff Oncology to Present at Upcoming Investor Conferences
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.